Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Steroid 17,20 lyase, also known as Cytochrome P450 17A1 (CYP17A1), is a crucial enzyme in steroid hormone biosynthesis. It catalyzes two key reactions: the 17α-hydroxylation of pregnenolone and progesterone, and the subsequent cleavage of the C17–C20 bond. It is essential for the production of glucocorticoids, mineralocorticoids, and sex steroids. Mutations or deficiencies in CYP17A1 can lead to sexual infantilism, pseudohermaphroditism, adrenal hyperplasia, and hypertension. Pharmacological inhibition is used in prostate cancer treatment.
CYP17A1 inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Steroid 17,20 Lyase (CYP17A1).